Original Research

Published on 03 Aug 2023

An attenuated herpesvirus vectored vaccine candidate induces T-cell responses against highly conserved porcine reproductive and respiratory syndrome virus M and NSP5 proteins that are unable to control infection

in Vaccines and Molecular Therapeutics

Rory C. F. de Brito
Kerry Holtham
Jessica Roser
Jack E. Saunders
Yvonne Wezel
Summer Henderson
Thekla Mauch
Beatriz Sanz-Bernardo
Jean-Pierre Frossard
Matthieu Bernard

Frontiers in Immunology

doi 10.3389/fimmu.2023.1201973

3,680 views
2 citations

Editorial

Published on 02 Aug 2023

Editorial: New-generation vaccines and novel vaccinal strategies against infectious diseases of livestock, wild and companion animals

in Vaccines and Molecular Therapeutics

Brad Pickering
Raúl Manzano-Román
Suresh Kumar Tikoo
Christophe Chevalier
Denis Archambault

Frontiers in Immunology

doi 10.3389/fimmu.2023.1256363

1,648 views

Original Research

Published on 01 Aug 2023

Single-cell RNA sequencing reveals the transcriptomic characteristics of peripheral blood mononuclear cells in hepatitis B vaccine non-responders

in Vaccines and Molecular Therapeutics

Meie Zhao
Chunxia Wang
Peiqiang Li
Tao Sun
Jing Wang
Shasha Zhang
Qinglong Ma
Fengdie Ma
Wenjing Shi
Maoning Shi

Frontiers in Immunology

doi 10.3389/fimmu.2023.1091237

4,055 views
3 citations

Clinical Trial

Published on 01 Aug 2023

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

in Vaccines and Molecular Therapeutics

Amir I. Tukhvatulin
Inna V. Dolzhikova
Alina S. Dzharullaeva
Daria M. Grousova
Anna V. Kovyrshina
Olga V. Zubkova
Ilya D. Zorkov
Anna A. Iliukhina
Artem Y. Shelkov
Alina S. Erokhova

Frontiers in Immunology

doi 10.3389/fimmu.2023.1228461

2,551 views
4 citations

Original Research

Published on 01 Aug 2023

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

in Vaccines and Molecular Therapeutics

Leyla Sharifi Aliabadi
Manoochehr Karami
Maryam Barkhordar
Seyed Saeed Hashemi Nazari
Amir Kavousi
Mohammad Ahmadvand
Mohammad Vaezi

Frontiers in Immunology

doi 10.3389/fimmu.2023.1237916

2,530 views
3 citations

Original Research

Published on 31 Jul 2023

Effects of Atrazine exposure on human bone marrow-derived mesenchymal stromal cells assessed by combinatorial assay matrix

in Vaccines and Molecular Therapeutics

Crystal C. Uwazie
Bonnie M. Pirlot
Tyler U. Faircloth
Mihir Patel
Rhett N. Parr
Halie M. Zastre
Peiman Hematti
Guido Moll
Devi Rajan
Raghavan Chinnadurai

Frontiers in Immunology

doi 10.3389/fimmu.2023.1214098

2,159 views
2 citations

Brief Research Report

Published on 31 Jul 2023

Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years

in Vaccines and Molecular Therapeutics

Hong-Hong Zhu
Guo-Qing Sun
Ji-Yu Wu
Su-Qing Fan
Ying-Ying Zhu
Zhi-Cheng Wang
Xiao-Fang Liao

Frontiers in Immunology

doi 10.3389/fimmu.2023.1212988

1,340 views
1 citation

Brief Research Report

Published on 27 Jul 2023

Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiency

in Vaccines and Molecular Therapeutics

Megha Tandon
Daniel V. DiGiacomo
Baijun Zhou
Paul Hesterberg
Chen E. Rosenberg
Sara Barmettler
Jocelyn R. Farmer

Frontiers in Immunology

doi 10.3389/fimmu.2023.1217718

1,612 views
2 citations

Original Research

Published on 27 Jul 2023

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption

in Vaccines and Molecular Therapeutics

Remigius Gröning
Andy Dernstedt
Clas Ahlm
Johan Normark
Peter Sundström
Mattias N. E. Forsell

Frontiers in Immunology

doi 10.3389/fimmu.2023.1219560

2,682 views
1 citation

Original Research

Published on 27 Jul 2023

A chimeric protein-based vaccine elicits a strong IgG antibody response and confers partial protection against Shiga toxin-producing Escherichia coli in mice

in Vaccines and Molecular Therapeutics

David A. Montero
Richard Garcia-Betancourt
Roberto M. Vidal
Juliana Velasco
Pablo A. Palacios
Daniela Schneider
Carolina Vega
Leonardo Gómez
Hernán Montecinos
Rodrigo Soto-Shara

Frontiers in Immunology

doi 10.3389/fimmu.2023.1186368

2,770 views
2 citations

Original Research

Published on 26 Jul 2023

Multi-phasic gene profiling using candidate gene approach predict the capacity of specific antibody production and maintenance following COVID-19 vaccination in Japanese population

in Vaccines and Molecular Therapeutics

Yuki Takemoto
Naoki Tanimine
Hisaaki Yoshinaka
Yuka Tanaka
Toshiro Takafuta
Aya Sugiyama
Junko Tanaka
Hideki Ohdan

Frontiers in Immunology

doi 10.3389/fimmu.2023.1217206

2,432 views
4 citations

Original Research

Published on 26 Jul 2023

Transcriptomic profile of TNFhigh MAIT cells is linked to B cell response following SARS-CoV-2 vaccination

in Vaccines and Molecular Therapeutics

Paolo Marzano
Simone Balin
Sara Terzoli
Silvia Della Bella
Valentina Cazzetta
Rocco Piazza
Inga Sandrock
Sarina Ravens
Likai Tan
Immo Prinz

Frontiers in Immunology

doi 10.3389/fimmu.2023.1208662

5,255 views
4 citations

Original Research

Published on 20 Jul 2023

Intranasal immunization with a Bucl8-based vaccine ameliorates bacterial burden and pathological inflammation, and promotes an IgG2a/b dominant response in an outbred mouse model of Burkholderia infection

in Vaccines and Molecular Therapeutics

Megan Grund
Soo Jeon Choi
Lillie Powell
Slawomir Lukomski

Frontiers in Immunology

doi 10.3389/fimmu.2023.1177650

1,734 views
4 citations

Original Research

Published on 20 Jul 2023

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines

in Vaccines and Molecular Therapeutics

Magdalena Mueller-Enz
Christina Woopen
Georges Katoul Al Rahbani
Rocco Haase
Marie Dunsche
Tjalf Ziemssen
Katja Akgün

Frontiers in Immunology

doi 10.3389/fimmu.2023.1081933

7,726 views
3 citations

Original Research

Published on 18 Jul 2023

A comparison of the binding sites of antibodies and single-domain antibodies

in Vaccines and Molecular Therapeutics

Gemma L. Gordon
Henriette L. Capel
Bora Guloglu
Eve Richardson
Ryan L. Stafford
Charlotte M. Deane

Frontiers in Immunology

doi 10.3389/fimmu.2023.1231623

5,657 views
11 citations

Clinical Trial

Published on 18 Jul 2023

Characterization of the humoral and cellular immunity induced by a recombinant BCG vaccine for the respiratory syncytial virus in healthy adults

in Vaccines and Molecular Therapeutics

Gaspar A. Pacheco
Catalina A. Andrade
Nicolás M.S. Gálvez
Yaneisi Vázquez
Linmar Rodríguez-Guilarte
Katia Abarca
Pablo A. González
Susan M. Bueno
Alexis M. Kalergis

Frontiers in Immunology

doi 10.3389/fimmu.2023.1215893

2,851 views
6 citations

Navigation group

Articles

An attenuated herpesvirus vectored vaccine candidate induces T-cell responses against highly conserved porcine reproductive and respiratory syndrome virus M and NSP5 proteins that are unable to control infection

Editorial: New-generation vaccines and novel vaccinal strategies against infectious diseases of livestock, wild and companion animals

Single-cell RNA sequencing reveals the transcriptomic characteristics of peripheral blood mononuclear cells in hepatitis B vaccine non-responders

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

Effects of Atrazine exposure on human bone marrow-derived mesenchymal stromal cells assessed by combinatorial assay matrix

Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years

Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiency

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption

A chimeric protein-based vaccine elicits a strong IgG antibody response and confers partial protection against Shiga toxin-producing Escherichia coli in mice

Multi-phasic gene profiling using candidate gene approach predict the capacity of specific antibody production and maintenance following COVID-19 vaccination in Japanese population

Transcriptomic profile of TNFhigh MAIT cells is linked to B cell response following SARS-CoV-2 vaccination

Intranasal immunization with a Bucl8-based vaccine ameliorates bacterial burden and pathological inflammation, and promotes an IgG2a/b dominant response in an outbred mouse model of Burkholderia infection

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines

A comparison of the binding sites of antibodies and single-domain antibodies

Characterization of the humoral and cellular immunity induced by a recombinant BCG vaccine for the respiratory syncytial virus in healthy adults